Syndromes of Dementia and Movement Disorders Market Size will Grow at 8.6% CAGR by 2020

The global treatment for syndromes of dementia and movement disorders market was valued at USD 12,859.8 million in 2014 and is expected to grow at a CAGR of 8.6% from 2014 to 2020, to reach an estimated value of USD 21,154.8 million in 2020.

The treatment for syndromes of dementia and movement disorders market is witnessing significant growth due to increasing R&D investments in drug discovery and developments. In addition, increasing prevalence of neurodegenerative disorders and rising awareness about mental disorders are also driving the growth of the market. However, most of the drugs fail in Phase III due to lack of sufficient knowledge about the mechanisms of the brain and the unknown causes of the disease. In addition, lack of comprehensive therapeutic management, strict regulations, and time-consuming drug approval process inhibit the growth of the market. The global treatment for syndromes of dementia and movement disorders market is anticipated to grow from an estimated USD 12,859.8 million in 2014 to USD 21,154.8 million in 2020 at a CAGR of 8.6% during the forecast period.

Browse Complete Report @ http://www.persistencemarketresearch.com/market-research/treatment-syndromes-dementia-movement-disorders-market.asp

In North America, growing aging population and rising incidence of neurodegenerative disease are driving the use of treatment for syndromes of dementia and movement disorders in the market. In addition, lack of proper medication is also fuelling the growth of treatments for syndromes of dementia and movement disorders market.

A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/2833

In Europe, the treatment for syndromes of dementia and movement disorders market is driven by rising incidence of mental disorder related disease and growing aging population. On the other hand, various awareness programs were launched by public and private health institutions to control dementia and movement disorders, which would increase the use of dementia and movement disorder drugs in the region.

However, in Asia the growth for treatment for syndromes of dementia and movement disorders is much higher than developed countries due to widening health insurance penetration, and large population base.

Request to view table of content @ http://www.persistencemarketresearch.com/market-research/treatment-syndromes-dementia-movement-disorders-market/toc

F. Hoffmann-La Roche, Ltd., Novartis AG, Merck & Co., Inc., Sanofi S.A., Valeant Pharmaceutical International, Inc., AstraZeneca GmbH and Pfizer, Inc. are some of the major players of treatment for syndromes of dementia and movement disorders market.

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.